1-(4-Phenylbenzoyl)piperazine-2,3-dicarboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-Phenylbenzoyl)piperazine-2,3-dicarboxylic acid
• 化学式: C₁₉H₁₈N₂O₅
• 分子量: 354.4
• InChiKey: TZKJHTCXJGVDCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Phenanthryl piperazinyl dicarboxylic acids as selective nmda receptor modulating agents
  申请人：——

  公开号：US20030078237A1

  公开（公告）日：2003-04-24

  Disclosed are compounds of formula (I) wherein: L is (a) optionally substituted by replacement of one or more of the hydrogen atoms on the phenanthrene ring system by one or more groups other than hydrogen; A is CH 2 , SO 2 or C═O; X is CO 2 H, PO 3 H 2 , PO 2 H 2 , PO 2 HR 5 , PO 2 HOR 5 , SO 3 H, SO 2 H, or tetrazole; and R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, alkenyl, alkynyl, aryl and aralkyl; or a pharmaceutically acceptable acid salt or base addition salt or an in vivo hydrolysable ester or amide thereof. Compounds of formula (I) are selective NMDA receptor modulating agents and, therefore, may be used to advantage in vitro in neuroassays and in vivo in the treatment of disorders of the CNS.

  公开了化合物的结构式(I)，其中：L是(a)通过将菲环上的一个或多个氢原子替换为一个或多个非氢基团而选择性地取代的；A是CH2，SO2或C═O；X是CO2H，PO3H2，PO2H2，PO2HR5，PO2HOR5，SO3H，SO2H或四唑；R1、R2、R3、R4和R5独立地选择自H、烷基、烯基、炔基、芳基和芳基烷基；或其药学上可接受的酸盐或碱加合盐或体内可水解的酯或酰胺。结构式(I)的化合物是选择性NMDA受体调节剂，因此，在神经分析中和中枢神经系统疾病的治疗中可以得到优势应用。
• Pharmaceutical composition effective in treatment of mechanical allodynia, screening method of potential compound as said pharmaceutical composition, inspection method of mechanical allodynia, and treatment method of mechanical allodynia
  申请人：——

  公开号：US20040254148A1

  公开（公告）日：2004-12-16

  The present invention aims to identify the molecule involved in mechanical allodynia, and to develop and provide a pharmaceutical composition to target this molecule such that the composition is effective in the treatment of mechanical allodynia. The present invention also aims to provide a screening method for compounds for use in such pharmaceutical compositions, a method of determining mechanical allodynia, and a treatment method of mechanical allodynia.

  本发明旨在确定参与机械异感症的分子，并开发和提供一种针对该分子的药物组合物，从而使该组合物能够有效治疗机械异感症。本发明还旨在提供一种用于此类药物组合物的化合物筛选方法、一种确定机械性异感症的方法以及一种治疗机械性异感症的方法。
• PHENANTHRYL PIPERAZINYL DICARBOXYLIC ACIDS AS SELECTIVE NMDA RECEPTOR MODULATING AGENTS
  申请人：UNIVERSITY OF NEBRASKA BOARD OF REGENTS

  公开号：EP1244638A2

  公开（公告）日：2002-10-02
• TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
  申请人：Sanomune Inc.

  公开号：EP2182978A1

  公开（公告）日：2010-05-12
• Methods for diagnosing and treating neuroendocrine cancer
  申请人：North William G.

  公开号：US20080145849A1

  公开（公告）日：2008-06-19

  The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.